Business
CEO Thomas Schinecker is signalling that historic investment in Switzerland cannot be sustained unless the country makes its investment and pricing environment more pharma-friendly.
While China is already a key market for AstraZeneca, the UK-based firm has announced a $15bn investment commitment in the country to boost its capabilities in cell therapy and radioconjugates.
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Boehringer Ingelheim hopes TPRC6 inhibition can provide a disease-modifying therapy for focal segmental glomerulosclerosis, which has no approved therapy. The smallest dose used in its Phase II study showed the highest response rate.
Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.
The US giant could pay up to $1.12bn to the German biotech after getting access to its programmable recombinase technology.
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Conclusion of India-EU talks sets ground for a free trade agreement to cut pharma tariffs, in turn lowering the cost for novel drugs like Novo’s obesity treatment Wegovy, though an investment protection agreement – likely influencing data exclusivity – will be concluded later.
The company announced Phase II data and plans for its registrational Phase III trial as CEO Mark Erlander and chief financial officer James Levine left the company.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
Plus deals involving Alfasigma/Innovative Molecules, Genethon/AskBio, XTL/NeuroNOS, ESTEVE/TerSera, Tahoe/Alloy, Bayer/Attralus and more.
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Deal Snapshot: The German group is the latest big pharma to partner with one of China's most prolific dealmakers in an agreement that could be worth over $1bn.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
The CytoDyn board of directors fired Nader Pourhassan in early 2022 as the company faced US FDA scrutiny over his comments about HIV and COVID-19 candidate leronlimab and as investors sued the firm.
Companies requiring follow-on financing were particularly hit in 2025, but the first signs of ‘pension power’ has given the UK sector hope of more investment.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.